top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


16/05/2026









ImPact Biotech’s padeliporfin VTP delivers 70% complete response with durable safety in Phase 3 LG‑UTUC, setting up 2027 regulatory submission and expansion into solid tumors (Ref)


Biotech’s updated Phase 3 ENLIGHTED trial data for padeliporfin VTP in low‑grade upper tract urothelial carcinoma (LG‑UTUC)


  • Efficacy


    • Complete response (CR): 70% (50/72) of evaluable patients achieved CR at the end of the Primary Response Evaluation (PRE).


    • Partial response (PR): 18% (13/72) achieved PR


    • Overall response rate: 88%


  • Durability


    • Maintenance Treatment Phase (MTP): 85.7% (18/21) sustained CRs for ≥12 months


    • Median duration of response: 23.9 months, with ongoing responses still observed


  • Safety


    • Well‑tolerated, consistent with prior data


    • Most adverse events were mild/moderate and procedure‑related, resolving within days


ImPact Biotech plans topline ENLIGHTED data later in 2026 and regulatory submission in 2027


  • Exploring commercialization partnerships


  • Expanding padeliporfin VTP into other solid tumors, including locally advanced pancreatic ductal adenocarcinoma (LA‑PDAC), with early signs of efficacy



Comments

bottom of page